预约演示
更新于：2026-02-27
Calcium Dobesilate
羟苯磺酸钙
更新于：2026-02-27
概要
基本信息
原研机构- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H12CaO10S2 |
InChIKeyAEWLOKQYGXDGFV-UHFFFAOYSA-N |
CAS号20123-80-2 |
关联
61
项与 羟苯磺酸钙 相关的临床试验NCT07390097
Effect of Perioperative Calcium Dobesilate on Postprocedural Pain, Symptom Relief, and Quality of Life After Radiofrequency Ablation for Great Saphenous Vein Insufficiency: A Randomized Controlled Trial
CTRI/2025/09/094079
A Prospective Randomized Double blind Comparative Multicentre Phase IV Clinical Trial to evaluate the Efficacy and Safety of SMUTHTM Capsule Calcium Dobesilate Monohydrate IP equivalent to Anhydrous Calcium Dobesilate 500mg Docusate Sodium IP 100 mg in comparison with Calcium Dobesilate 500 mg in the treatment of patients with haemorrhoids. - NIL
ChiCTR2500111279
Optimization of Microcirculation Disorder in Non-proliferative Diabetic Retinopathy by Combination of Traditional Chinese and Western Medicine: Analysis of the Efficacy Difference between Tongluo Mingmu and Danshen Preparation Combined with Calcium Dobesilate
100 项与 羟苯磺酸钙 相关的临床结果
登录后查看更多信息
100 项与 羟苯磺酸钙 相关的转化医学
登录后查看更多信息
100 项与 羟苯磺酸钙 相关的专利（医药）
登录后查看更多信息
303
项与 羟苯磺酸钙 相关的文献（医药）2025-12-09Cureus Journal of Medical Science
Diverse and Atypical Presentations of Acroangiodermatitis of Mali: Diagnostic Insights From Three Cases
Article
作者: Dennis Joseph, Leena ; Rangarajan, Sudha ; Swaminathan, Adikrishnan ; Peddireddy, Greeshma ; Raviprakash, Divya
Acroangiodermatitis is an uncommon, benign vasoproliferative entity that often develops in the setting of long-standing venous hypertension or arteriovenous abnormalities. Its clinical resemblance to other dermatoses often results in misdiagnosis and delayed treatment. We describe three cases, two males and one female, who presented with persistent lower limb lesions. Clinical findings included hyperpigmented plaques, indurated plaques, and erythematous soft nodules localized to the legs. Clinically, varicosities were evident in two of the three cases, and one patient had previously undergone surgical vein stripping for the same. Given the chronicity of lesions, biopsies were performed. Histopathological features were consistent with acroangiodermatitis, while dermoscopy showed vascular patterns along with white, structureless areas. Venous Doppler ultrasound confirmed the underlying venous insufficiency in all three cases. Based on clinical, dermoscopic, histopathological, and radiological evaluation, a final diagnosis of acroangiodermatitis of Mali was made. The patients were started on oral calcium dobesilate and topical corticosteroids and were referred for vascular surgical evaluation. This case series highlights the importance of recognizing the diverse and atypical presentations of acroangiodermatitis of Mali, emphasizing that biopsy and dermoscopy are critical for a definitive diagnosis.
2025-09-05SCHWEIZER ARCHIV FUR TIERHEILKUNDE
Pharmacokinetics of orally administered calcium dobesilate in Warmblood horses
Article
作者: Fürst, A E ; Montavon, P M ; Montavon, S ; Bakony, M ; Harder, J ; Lanyi, K
INTRODUCTION:
Calcium dobesilate has recently been used for treating lameness in horses because it enhances microvascular processes and reduces intraosseous pressure. Lameness caused by disorders in bone metabolism and increased intraosseous pressure, such as navicular disease, osseous cyst-like lesions and pedal bone oedema, are commonly treated with rest, anti-inflammatory agents and surgery. Calcium dobesilate has the potential to influence the pathophysiology of these diseases, thereby improving healing. To determine whether calcium dobesilate and its acting agent calcium 2,5-dihydroxybenzene sulfonate (2,5HBSA) is absorbed by the equine gastrointestinal system to generate detectable plasma concentrations. The study was designed as a prospective in-vivo study. Eight healthy adult Swiss Warmblood horses were used in the study. Calcium dobesilate (3 mg/kg, PO, q12h) was administered orally in mash for seven days. Blood samples were collected from a jugular vein after the last dose of calcium dobesilate. All horses underwent daily physical examination and haematological and blood chemical analyses before and after the study. Liquid chromatography was used to determine plasma concentrations of 2,5HBSA. Noncompartmental analysis was used to estimate the pharmacokinetic parameters. 2,5HBSA was detected in plasma samples after oral administration and ranged from 2300 ng/ml to 3600 ng/ml with a mean of 2900 ng/ml. The results of haematological and plasma biochemical testing were within the reference limits at all times, and no adverse effects occurred. Only plasma samples were analysed and calcium dobesilat was only measured after the treatment period of seven days. Calcium dobesilate was absorbed by the equine gastrointestinal system and reached detectable plasma concentrations.
2025-07-01JOURNAL OF MOLECULAR STRUCTURE
Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples
作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir
The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R2 = 0.9984).The detection and quantification limits were 1.66 x 10-6 and 2.71 x 10-5 mM, resp.The binding constant (Ka) was 9.8 x 104 M-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.
100 项与 羟苯磺酸钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉硬化闭塞症 | 中国 | 1992-07-04 | |
| 慢性静脉功能不全 | 中国 | 1992-07-04 | |
| 高血压 | 中国 | 1992-07-04 | |
| 微血管疾病 | 中国 | 1992-07-04 | |
| 静脉炎 | 中国 | 1992-07-04 | |
| 痉挛 | 中国 | 1992-07-04 | |
| 溃疡 | 中国 | 1992-07-04 | |
| 静脉曲张 | 中国 | 1992-07-04 | |
| 糖尿病性视网膜病变 | 韩国 | 1988-01-19 | |
| 水肿 | 韩国 | 1988-01-19 | |
| 痔疮 | 韩国 | 1988-01-19 | |
| 血栓后综合征 | 韩国 | 1988-01-19 | |
| 静脉功能不全 | 韩国 | 1988-01-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病肾病 | 临床前 | - | 2018-10-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用